Three-Year trial tests new therapy to prevent dangerous bleeds
NCT ID NCT03879135
Summary
This study tested the long-term safety and effectiveness of a replacement therapy called rVWF (vonicog alfa) for people with severe von Willebrand disease (VWD), a disorder that prevents blood from clotting properly. The main goal was to see how well regular, preventive infusions of this therapy could reduce the rate of spontaneous bleeding episodes over time. The study followed 38 participants, including children and adults, for up to three years to monitor their bleeding rates and any side effects from the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH - Medizinische Universität Wien
Vienna, Austria
-
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, 72202, United States
-
Azienda Ospedaliera Pediatrica Santobono Pausillipon
Naples, Italy
-
Azienda Ospedaliera Universitaria Careggi
Florence, 50134, Italy
-
Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza
Roma, 00185, Italy
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Ege University Medical Faculty
Izmir, 35040, Turkey (Türkiye)
-
Ege University Medical Faculty
Izmir, 35100, Turkey (Türkiye)
-
Erasmus Medisch Centrum
Rotterdam, 3015 AA, Netherlands
-
Erasmus Medisch Centrum
Rotterdam, 3015 CN, Netherlands
-
FSBI of Science "Kirov Scientific and Research Institute of Hematology and Blood Transfusion of FMBA
Kirov, 610017, Russia
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, 00168, Italy
-
Groupe Hospitalier Pellegrin - Hôpital Pellegrin
Gironde, France
-
Groupement Hospitalier Est- Hôpital Louis Pradel
Bron, 69677, France
-
Groupement Hospitalier Sud - Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270, France
-
Hopital Cardiologique - CHU Lille
Lille, Nord, France
-
Hospital General Universitario de Alicante
Alicante, 03010, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hôpital Necker - Enfants Malades
Paris, Paris, 75015, France
-
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, 46260, United States
-
Istanbul University Oncology Institute
Istanbul, Turkey (Türkiye)
-
Klinikum der Johann Wolfgang Goethe-Universitaet
Frankfurt, Germany
-
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Ondokuz Mayis Univ. Med. Fac.
Samsun, 55139, Turkey (Türkiye)
-
Ospedale Pediatrico Bambino Gesù
Roma, Italy
-
Rainbow Babies and Children's Hospital
Cleveland, Ohio, 44106, United States
-
SAIH "Kemerovo Regional Clinical Hospital"
Kemerovo, 650066, Russia
-
University of Colorado Health
Aurora, Colorado, 80045, United States
-
University of Florida College of Medicine
Gainesville, Florida, 32610, United States
-
Werlhof-Institut GmbH
Hanover, Germany
Conditions
Explore the condition pages connected to this study.